Parikumar Periasamy, Haraguchi Kazutoshi, Senthilkumar Rajappa, Abraham Samuel Jk
The Light Eye Hospital Dharmapuri, India.
The Light and Light Ventures Limited Croydon, The United Kingdom.
Am J Stem Cells. 2024 Jun 15;13(3):162-168. doi: 10.62347/CBYH7014. eCollection 2024.
Post-corneal transplantation endothelial decompensation and subsequent bullous keratopathy often result in unfavorable clinical outcomes regardless of the treatment strategy employed. In this report, we present the outcomes of a patient managed with in vitro expanded human corneal endothelial cell (HCEC) transplantation facilitated by a nanocomposite gel (NC gel) sheet over 16 years. A 40-year-old male patient who presented with signs of graft failure after penetrating keratoplasty underwent HCEC transplantation. Additionally, HCECs were obtained from a deceased donor, cultured in vitro, and transplanted onto an NC gel sheet as a temporary scaffold to support the transplanted cells until engraftment. At the 16-year follow-up, the cornea had remained stable and did not exhibit active disease manifestations. Notably, no new bullae were formed, and the epithelial surface appeared smooth without signs of active fluid transport abnormalities. Although a slight reduction in corneal thickness was observed, the disease-free region at the time of the intervention remained transparent. HCEC transplantation with NC gel sheets is a promising, minimally invasive approach for achieving long-term corneal stability in cases of bullous keratopathy following corneal graft failure. Importantly, this technique circumvents the need for complex procedures and utilizes corneal endothelial precursors derived from donor corneas discarded for lack of sufficient endothelial cells. After in vitro culture, these cells were successfully transplanted in three patients, proving that one donated eye can be useful in treating three eyes of three patients. This technique addresses the donor cornea shortage concerns and makes our concept "an-eye-for-eyes", a reality.
角膜移植术后内皮失代偿及随后的大泡性角膜病变,无论采用何种治疗策略,往往都会导致不良的临床结果。在本报告中,我们介绍了一名患者在纳米复合凝胶(NC凝胶)片辅助下接受体外扩增人角膜内皮细胞(HCEC)移植治疗16年的结果。一名40岁男性患者在穿透性角膜移植术后出现移植失败迹象,接受了HCEC移植。此外,从已故供体获取HCEC,在体外培养,然后移植到NC凝胶片上作为临时支架,以支持移植的细胞直至植入。在16年的随访中,角膜保持稳定,未出现活动性疾病表现。值得注意的是,没有形成新的大泡,上皮表面光滑,没有活动性液体转运异常的迹象。虽然观察到角膜厚度略有减少,但干预时的无病区域仍保持透明。在角膜移植失败后发生大泡性角膜病变的情况下,使用NC凝胶片进行HCEC移植是一种有前景的、微创的方法,可实现角膜的长期稳定。重要的是,该技术避免了复杂的手术过程,利用了因内皮细胞不足而被丢弃的供体角膜来源的角膜内皮前体细胞。体外培养后,这些细胞成功移植到三名患者体内,证明一只捐献的眼睛可用于治疗三名患者的三只眼睛。该技术解决了供体角膜短缺的问题,使我们“以眼还眼”的理念成为现实。